Evidence map›Paper›PMID 34581471›Full record

ArticleAngewandte Chemie (International ed. in English)2021

Inhibition Mechanism of SARS-CoV-2 Main Protease with Ketone-Based Inhibitors Unveiled by Multiscale Simulations: Insights for Improved Designs*.

Carlos A Ramos-Guzmán, J Javier Ruiz-Pernía, Iñaki Tuñón

Open access · hybridAbstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Review
  3. CHARMM-GUIJournal of chemical theory and computation · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Electrostatic Embedding of Machine Learning Potentials.Journal of chemical theory and computation · 2023
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Carlos A Ramos-GuzmánDepartamento de Química Física, Universidad de Valencia, 46100, Burjassot, Spain.ORCID 0000-0002-7701-377X
J Javier Ruiz-PerníaDepartamento de Química Física, Universidad de Valencia, 46100, Burjassot, Spain.ORCID 0000-0002-4640-0419
Iñaki TuñónDepartamento de Química Física, Universidad de Valencia, 46100, Burjassot, Spain.ORCID 0000-0002-6995-1838
Universitat de València · ES

Funding

generalitat valenciana GVCOV19/Decreto180/2020Ministerio de Ciencia Innovación y Universidades (Spain) PGC2018-094852-B-C22
6 · The paper itself

Abstract

We present the results of classical and QM/MM simulations for the inhibition of SARS-CoV-2 3CL protease by a hydroxymethylketone inhibitor, PF-00835231. In the noncovalent complex the carbonyl oxygen atom of the warhead is placed in the oxyanion hole formed by residues 143 to 145, while P1-P3 groups are accommodated in the active site with interactions similar to those observed for the peptide substrate. According to alchemical free energy calculations, the P1' hydroxymethyl group also contributes to the binding free energy. Covalent inhibition of the enzyme is triggered by the proton transfer from Cys145 to His41. This step is followed by the nucleophilic attack of the Sγ atom on the carbonyl carbon atom of the inhibitor and a proton transfer from His41 to the carbonyl oxygen atom mediated by the P1' hydroxyl group. Computational simulations show that the addition of a chloromethyl substituent to the P1' group may lower the activation free energy for covalent inhibition.

Indexed as

Drug DesignBinding SitesCatalytic DomainCoronavirus 3C ProteasesCOVID-19COVID-19 Drug TreatmentHumansKetonesKineticsMolecular Dynamics SimulationProtease InhibitorsSARS-CoV-2Thermodynamics3C-like proteinase, SARS-CoV-2Coronavirus 3C ProteasesKetonesProtease Inhibitors3CL proteaseinhibitorsmolecular modelingPF-00835231SARS-CoV-2

Identifiers

PMID34581471
PMCPMC8653175
OpenAlexW3204146108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.